RhumbLine Advisers
AYTU icon

RhumbLine Advisers’s AYTU BioPharma AYTU Stock Holding History

RhumbLine Advisers’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-692
Closed -$105K – 2994
2021
Q1 		$105K Buy
+692
New +$110K ﹤0.01% 2931
2020
Q4 		– Sell
-105
Closed -$25K – 3042
2020
Q3 		$25K Sell
105
-38
-27% -$9.77K ﹤0.01% 2967
2020
Q2 		$41K Buy
+143
New +$43.3K ﹤0.01% 3038

Other funds holding AYTU

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RhumbLine Advisers's AYTU Position: Q2 2021 in Review

RhumbLine Advisers sold out of AYTU BioPharma (AYTU) in Q2 2021, closing a stake of 692 shares — an estimated $105K sold.

RhumbLine Advisers first reported a position in AYTU in Q2 2020 and held it in 3 quarters. The position peaked at $105K in Q1 2021. 50 funds tracked by Wall St. Rank hold AYTU as of Q2 2021.

  • RhumbLine Advisers reported no remaining AYTU BioPharma position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 692 AYTU BioPharma shares in Q2 2021, an estimated $105K.
  • RhumbLine Advisers first reported a position in AYTU BioPharma in Q2 2020 and held it in 3 quarters.
  • RhumbLine Advisers's AYTU BioPharma position peaked at $105K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.